Commercial Supporter
Sanofi and Regeneron Pharmaceuticals
Education Partner
Pri-Med Institute
Education Resource Partner
National Eczema Association
Curriculum
1.50 CME Credit
Explore the sessions within this interactive curriculum to advance your knowledge of atopic dermatitis (AD). Through case-based discussions, you will master the science of distinguishing atopic dermatitis from other conditions. You will also develop the tools necessary to devise evidence-based individualized treatment plans for moderate-to-severe AD that account for patient preferences and treatment goals. Elevate your practice and optimize patient outcomes with this dynamic learning experience.
1.50 AMA PRA Category 1 Credits, 1.50 ABIM MOC or 1.52 AANP, including 0.93 AANP Pharm
Release Date: 7/31/2023
Available for credit until 7/31/2024
Clinical Coffee Break
0.50 CME/MOC
0.49 AANP | 0.32 Pharmacology
Clinical Coffee Break
0.50 CME/MOC
0.57 AANP | 0.38 Pharmacology
Interactive Learning
0.50 CME/MOC
0.46 AANP | 0.23 Pharmacology
Clinical Associate Professor of Family and Community Medicine, Sidney Kimmel Medical College at Thomas Jefferson University
Associate Director, Family Medicine Residency Program, Abington – Jefferson Health
Attending Physician, Lurie Children’s Hospital
Assistant Professor of Pediatrics and Dermatology,
Northwestern University Feinberg School of Medicine
Dermatologist & Pediatric Dermatologist
Ada West Dermatology
St. Luke’s Children’s Hospital
Sanofi and Regeneron Pharmaceuticals
Pri-Med Institute
National Eczema Association
The preferred browser is Google Chrome. If using a different browser, such as Safari, Firefox or Edge, make sure you are using the most up-to-date version. Your Internet settings should be set to accept cookies and JavaScript. If cookies and/or JavaScript are disabled, the site may not function properly. A high-speed Internet connection is not required; however, it is recommended for faster download times.
The opinions, ideas, and recommendations expressed in this educational activity are those of the faculty only and are not necessarily endorsed by, nor do they necessarily reflect, those of their affiliated institutions, Pri-Med Institute, Pri-Med Institute Advisory Boards and Consultants, DBC Pri-Med, LLC.
Clinical judgment must guide each clinician in weighing the possible risks, benefits, or contraindications of any diagnostics, interventions or treatments discussed. Clinicians should review manufacturers’ product information and consider these with the recommendations of other authorities when applying the assessment and/or clinical management strategies discussed in this activity to the care of their patients.
Pri-Med Institute educational activities are developed and conducted in accordance with the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. It is the mission of Pri-Med Institute to develop and present educational activities that are timely, fair-balanced, scientifically rigorous, and that serve to improve patient outcomes. To that end, we welcome your comments about how to better serve your needs.
Pri-Med Institute Accredited Provider
Pri-Med programs are owned and operated by DBC Pri-Med, LLC, a division of Diversified Communications, Inc. Pri-Med Institute, the accredited division of Pri-Med, is accredited with commendation by the ACCME and approved as a provider of continuing education by the AANP.
Disclosures and Conflict of Interest
Pri-Med Institute requires all individuals in a position to influence educational content for Pri-Med Institute-certified CME/CE activities to disclose personal financial relationships with commercial interests or ineligible companies prior to contributing to its educational activities. Pri-Med Institute assesses disclosed relationships and follows a defined process to mitigate real or implied conflicts to ensure, to the best of its ability, that all educational content is free of commercial bias. All relevant financial relationships have been mitigated Financial disclosures for everyone in control of educational content are provided before the start of each CME/CE activity.
Discussion of Off-Label Uses and Investigational Products
During the course of their presentations, the faculty may mention uses of products that have not been approved in the United States for the indication(s) being discussed. All presenters are instructed to notify participants when they are discussing unapproved uses or investigational agents. In addition, specific slides will include notation of the off-label use or investigational agent being discussed. Views presented related to unapproved uses of products are solely those of the presenter(s) and are not endorsed by Pri-Med Institute or DBC Pri-Med, LLC.
Questions?
If you have questions about this activity, please email support@pri-med.com or call (877) 477-4633.